Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) fell 1% during trading on Monday . The stock traded as low as $62.26 and last traded at $63.19, with a volume of 191,249 shares. The stock had previously closed at $63.85.

Several brokerages recently commented on ONCE. Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Wedbush reaffirmed an “underperform” rating and set a $29.00 price objective (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $94.00 price objective on shares of Spark Therapeutics in a research note on Thursday, August 11th. Chardan Capital set a $35.00 price objective on Spark Therapeutics and gave the stock a “hold” rating in a research note on Thursday, July 21st. Finally, SunTrust Banks Inc. raised their price objective on Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a research note on Tuesday, June 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $62.27.

The firm’s 50-day moving average is $58.88 and its 200 day moving average is $47.34. The company’s market capitalization is $1.98 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $0.07. Spark Therapeutics had a negative return on equity of 26.96% and a negative net margin of 366.76%. The business earned $1.29 million during the quarter, compared to the consensus estimate of $1.17 million. During the same period in the prior year, the firm earned ($0.60) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts expect that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current fiscal year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 10,000 shares of the company’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $62.68, for a total transaction of $626,800.00. Following the sale, the chief executive officer now owns 240,000 shares of the company’s stock, valued at $15,043,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anand Mehra sold 22,665 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $60.03, for a total transaction of $1,360,579.95. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada raised its position in shares of Spark Therapeutics by 1,346.2% in the second quarter. Royal Bank of Canada now owns 11,280 shares of the company’s stock valued at $577,000 after buying an additional 10,500 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Spark Therapeutics by 50.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 62,288 shares of the company’s stock valued at $3,185,000 after buying an additional 20,920 shares in the last quarter. Legal & General Group Plc raised its position in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock valued at $138,000 after buying an additional 1,394 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Spark Therapeutics by 63.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 12,778 shares of the company’s stock valued at $653,000 after buying an additional 4,955 shares in the last quarter. Finally, Iguana Healthcare Management LLC bought a new position in shares of Spark Therapeutics during the second quarter valued at $3,068,000. 78.79% of the stock is currently owned by institutional investors and hedge funds.

About Spark Therapeutics

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.